Abstract: E-CFCP also reduced HBVETV-RL180M/S202G/M204V-viremia by 2 logs over 2 weeks, while ETV completely failed to reduce HBVETV-RL180M/S202G/M204V-viremia.
Abstract: E-CFCP's 4'-cyano and fluorine interact with both HBVWT-RT and HBVETV-RL180M/S202G-M204 -RT via Van der Waals and polar forces, being important for E-CFCP-triphosphate's interactions and anti-HBV potency.
Abstract: RESULTS: E-CFCP potently blocked HBVWTD1 production (IC50qPCR_cell=1.8 nM) in HepG2.2.15 cells and HBVWTC2 (IC50SB_cell=0.7 nM), entecavir (ETV)-resistant HBVETV-RL180M/S202G/
Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region.
Method: According to the most recent clinical practice guidelines of the European Association for the Study of the Liv
Result: Overall, rtL180M, rtA181T/V, rtT184G/S, rtS202G/I, rtM204I, rtM204V, rtN236T, and rtM250V were more frequently detected in genotypes A (13.9%), C (0.8%), D (0.1%), H (3.8%), G (25%), A (13.1%), B (0.7%), and C (0.1%), respectively.
Table: L180M
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Introduction: The amino acid substitutions, M204V/I and M204V/I + L180M, in HBV RT are known to cause 3TC resistance, and these mutations significantly reduce ETV effectiveness against HBV, thereby increasing the likelihood of subsequently developing greater ETV resistance through getting additional amino acid substitutions such as S202G in HBV RT.
Result: The corresponding M204V/I mutation in HBV RT has
7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Abstract: Southern blot analysis using wild-type HBV (HBVWT)-encoding-plasmid-transfected HepG2 cells revealed that CdFA efficiently suppresses the productio
Method: Plasmids carrying the 1.24-fold HBV genomes of a wild-type genotype Ce strain (HBVWTCe), entecavir-resistant strain carrying L180M/S202G/M204V substitutions (HBVETVR), or adefovir-resistant strain carrying A181T/N236T substitutions (HBVADVR) were constructed for in vitro study as previously described.
Result: We then analyzed the interactions of ETV-TP and CdFA-TP with HBV-RT, in which three amino acid substitutions associated with HBV's resistance to ETV (L180M/S202G/M204V) have been introduced (RTETV-R).
Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
Abstract: Several lamivudine-associated HBV resistance mutations, including L180M, A181T, M204I, and M204V, were observed.
Result: Analysis of polymerase gene sequences from baseline and follow-up samples showed the presence of resistance-associated mutations in 5 of these 6 patients, including L180M, A181T, M204I, and M204V (Table 5).
Result: Patient ZA113 had the L180M mutation and the L180M + M204V mutations at the 12- and 18-month follow-up visits, respectively, with HBV viremia increasing from 1.99 x 104 IU/mL at baseline to 7.08 x 106 at the 18-month follow-
COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B.
Discussion: Among those mt, we found only 2 cases of respective HBV genotypes B and C that have rtM204V and rtM204I primary mt coexisting with rtL180M compensatory/secondary mt.
Discussion: Multiple-point mt are found to be rare, including rtV207M + rtV207I; rtV207M + rtS213T; rtV207M + rtL229V; rt PMID: 32765014
2020
Infection and drug resistance
Abstract: Primary and secondary DR variants were found in 7.3% (15/206) of patients, including rtL80I/V, rtI169T, rt
Result: Primary and/or secondary DR variants were found in 7.3% (15/206) of patients, and included rtL80I/V, rtI169T, rtV173L, rtL180M, rtA181T/V, rtM204I/V, and rtN236T.
Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
Abstract: Resistance mutations included Table: L180M
Discussion: Although decreased susceptibility to ETV may be expected in presence of HBV rtM204V and rtL180M mutants, doubling the dose of ETV overcomes the effects of these two mutations.
Discussion: Resistance to lamivudine is best recognized in association with the rtM204V/I mutation, which is also associated with decreased viral replication fitness, leading to the subsequent selection of the compensatory mutants rtL180M, rtV173L, and rtL80I/V.
Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations.
PMID: 32994690
2020
World journal of gastroenterology
Result: sA159V+rtL180M+rtM204V (35%), rtL180M+rtM204V (35%), sA159V+rtM204I (15%), s Result: In sample A-S3, sA159V+rtL180M+rtM204V+rtT184L was the most abundant (Figure 1A).
HBV mutation literature information.
PMID: 
2021
Journal of hepatology
Browser Board
Co-occurred Entities
Filtrator
ViMRT